KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

Clinical trial NCT06767046 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06767046
Sponsor: Corregene Biotechnology Co., Ltd
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Colorectal Pancreatic Non-small Cell Lung Cancer (NSCLC)

Start date: 2025-02-18
Primary completion: 2028-11-30
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.